Figure 3 from First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
Authors:
- Nehal J. LakhaniNLNehal J. Lakhani
- Kyriakos P. PapadopoulosKPKyriakos P. Papadopoulos
- Melissa Lynne JohnsonMJMelissa Lynne Johnson
- Haeseong ParkHPHaeseong Park
- Ding WangDWDing Wang
- Timothy A. YapTYTimothy A. Yap
- Afshin DowlatiADAfshin Dowlati
- Robert G. MakiRMRobert G. Maki
- Susanna UlahannanSUSusanna Ulahannan
- Filipa LynceFLFilipa Lynce
- Karen KellyKKKaren Kelly
- Stephen WilliamsonSWStephen Williamson
Open Access
- 16 December 2024
- other
- Published by American Association for Cancer Research (AACR)